Zhenale

Quick links to important sections

Zhenale

Selected form

Medically reviewed

Marina Burgos

Last updated on 10/01/2026

This page provides general, reference-level information compiled from official medical sources. It is not a substitute for professional medical advice, diagnosis, or treatment. For decisions about your health, please consult a qualified healthcare professional.

Overview of Zhenale

Quick Facts

Property Description
Active Ingredient Mifepristone (a substituted 19-nor steroid)
Form Tablet (intended for oral administration)
Pharmacological Class Progestin Antagonist (Antiprogestogen)
Origin Synthetic steroid
Primary Function Hormonal interference for specific medical applications

Zhenale: Definition, Composition, and Pharmaceutical Type

Zhenale is a prescription-only medicinal product administered as an oral tablet. Its sole active component is Mifepristone, a powerful and chemically defined synthetic steroid also recognized by the designation RU-486. This agent is distinctly positioned as a single-ingredient formulation, confining its effects entirely to the action of the Mifepristone component alone. Its composition is consistently manufactured as a defined oral solid dose suitable for ingestion. The established quality of the Mifepristone compound is clinically recognized for its predictable binding affinity to target receptors, supporting its use in sensitive medical applications.

Pharmacological Class: What Type of Hormone Blocker is Zhenale?

Zhenale belongs to the major pharmacological class known as Progestin Antagonists, often termed an Antiprogestogen. This classification means the drug's primary action is to competitively block the cellular receptors (PR) intended for the natural hormone progesterone, which inhibits progesterone's normal biological effects. Pharmacological properties indicate that Mifepristone effectively serves as a progesterone blocker in the body. Due to its structural similarity, Mifepristone also exhibits potent Antiglucocorticoid activity, acting as a Cortisol receptor blocker. This dual-receptor activity is key to its mechanism, preventing both progesterone and cortisol from exerting their effects when the medicine is present.

General Therapeutic Function and Purpose

The general therapeutic purpose of this medication arises directly from its established Antiprogestogen mechanism, serving to interrupt specific hormonal processes. This action forms the basis for its primary function as an agent used in pregnancy termination (medical abortion), which represents a typical use scenario for this specific drug class. Furthermore, because of the drug’s confirmed ability to act as a Cortisol receptor blocker, it is also utilized for the management of certain endocrine imbalances characterized by excess cortisol activity, such as Hypercortisolism. The drug's function is strictly confined to temporary, defined hormonal interference.

What side effects are possible with Zhenale?

Possible Side Effects and Safety Information

The official regulatory safety documents structure the possible adverse effects of Zhenale (Mifepristone) according to the body system affected and the frequency of occurrence. This classification reflects two distinct risk profiles: one for short-term, low-dose use and another for chronic, high-dose use.


Frequency and System-Organ Classes

The most frequently documented reactions are typically associated with hormonal interruption. Very Common (ge 1 in 10 patients) effects include abdominal pain (cramping) and heavy uterine bleeding. Common (ge 1 in 100 to < 1 in 10 patients) events often involve Gastrointestinal disorders such as nausea, vomiting, and diarrhea, as well as Nervous System disorders like headache and dizziness.

Classification System-Organ Class Examples
Very Common Reproductive System and Breast Disorders
Common Gastrointestinal, Nervous System
Uncommon Infections and Infestations (e.g., Endometritis)

Serious Adverse Reactions and Constraints

The regulatory labeling defines specific serious adverse reactions. These include Significant Hemorrhage and a rare risk of Serious Infection/Sepsis, particularly in the context of the short-term use. For high-dose, long-term use, the principal serious risk is Adrenal Insufficiency, stemming from the drug's Antiglucocorticoid action. This context is also associated with metabolic concerns such as Hypokalemia and Hypertension.

Safety documents also list specific restrictions. The medicine is restricted for use in patients with severe hepatic impairment, chronic adrenal failure, or pre-existing known hemorrhagic disorders due to safety concerns. The safety documentation communicates these risks in a neutral, factual manner, allowing for a structured assessment of the medicine's risk profile.

Overdose and Emergency Response

Zhenale Overdose and When to Seek Help

Domain Official Regulatory Statement
Documented Overdose Presentations Primarily characterized by clinical signs and symptoms of adrenal impairment (hypoadrenalism) resulting from prolonged, high-dose exposure.
Physiological Systems Affected Endocrine system, specifically the cortisol axis, due to the drug's potent Antiglucocorticoid activity.
Emergency-Response Statements Management should be symptomatic and supportive, including corrective treatment for hormonal deficiency.
When Immediate Medical Help is Required Patients must seek immediate medical attention for suspected overdose or if signs of hypoadrenalism are observed.

Overdose Classifications

Classification Official Regulatory Statement
Severity Classification Overdose poses the risk of severe complications due to endocrine disruption, necessitating close observation.
Overdose-Context Constraints No specific antidote is known; treatment relies on supportive measures and the administration of glucocorticoid therapy to correct the documented deficiency.

Resulting Overdose Structure

Official overdose statements confirm that excessive exposure to Zhenale is documented to cause clinical manifestations of adrenal impairment. This specific physiological consequence arises from the drug's impact on the endocrine system, and in cases of high-dose exposure, it may lead to severe complications. The regulatory documentation requires patients to seek immediate medical attention for any suspected overdose or when symptoms related to hormonal deficiency are observed. Since no specific antidote is known, the required management procedure, as outlined in official labeling, focuses on symptomatic and supportive treatment, including the specialized correction of hypoadrenalism. Special consideration for managing the correction of hypoadrenalism is noted for patients with pre-existing Hypercortisolism who experience excessive exposure.

Therapeutic Uses of Zhenale

Zhenale (Mifepristone) is considered relevant across medical domains involving specific hormonal conditions. The application of this medication is generally relevant in contexts involving specific hormonal shifts to address defined clinical states, including the non-surgical management of early pregnancy and the management of challenging systemic symptoms related to Hypercortisolism (Cushing’s Syndrome).

This medication is applied across therapeutic areas where short-term symptom management or defined hormonal interruption is appropriate. “The use supports a defined process for addressing the established reproductive status, assisting with an alternative approach for patients seeking this specific intervention.” For endocrine patients, its use plays a role in managing symptoms related to health issues such as systemic imbalance that arise from excess cortisol. The core benefit contributes to easing the overall symptom load related to these systemic functions and helps maintain a sense of stability.


Quick Fact: Relief for Systemic Imbalance
Zhenale helps maintain a sense of stability during chronic conditions where symptoms are caused by hormonal overactivity.

Regulatory References

  1. NIH MedlinePlus Drug Information

Eligibility and Restrictions for Use

Who Can and Cannot Use Zhenale?

Eligibility Status

Category Regulatory Status (Population Eligibility)
Contraindicated Populations Chronic adrenal failure or concurrent long-term corticosteroid therapy; Hemorrhagic disorders or concurrent anticoagulant therapy; Inherited porphyrias; Known hypersensitivity to the drug or prostaglandins.
Pregnancy/IUD Exclusion Confirmed or suspected ectopic pregnancy and IUD in place (for termination use). Pregnancy is contraindicated when the drug is used for Hypercortisolism management.
Organ Function Restrictions Severe hepatic impairment is not recommended. For both renal and hepatic impairment (mild-to-moderate), the maximum daily dose is limited to 600 mg (for Hypercortisolism use).
Age-Related Status Use is not established in the general pediatric (non-pregnant) and geriatric (over 65) populations due to insufficient data.

Summary of Official Eligibility Profile

Official regulatory documents establish absolute exclusions for patient groups with specific chronic conditions or physiological states. This medicine is contraindicated if the patient has adrenal failure, a bleeding disorder, or an ectopic pregnancy. Furthermore, eligibility is restricted based on organ function, with use limited or not recommended in cases of severe renal or hepatic impairment. Treatment also requires the patient to have immediate access to emergency medical facilities.

What should I know about interactions with other medicines?

Zhenale's interaction profile is defined by its substantial influence on drug metabolism and specific pharmacodynamic effects, requiring formal constraints on co-administration as documented in regulatory labeling.

Contraindicated Combinations

Certain combinations are officially prohibited due to severe interaction risks. Concurrent long-term Corticosteroid Therapy is contraindicated because Zhenale’s antiglucocorticoid activity will antagonize the corticosteroid’s intended effect. For systemic imbalance management, co-administration with strong CYP3A Inducers (e.g., Rifampin, Phenytoin) is prohibited as they significantly reduce Zhenale's plasma exposure. Similarly, specific CYP3A Substrates (e.g., Simvastatin, Lovastatin) are contraindicated as Zhenale will cause a dangerous increase in their concentrations. Use in patients with Hemorrhagic Disorders or Concurrent Anticoagulant Therapy is restricted for certain uses due to the risk of bleeding.

Metabolic and Exposure Interactions

Zhenale is a potent inhibitor of CYP3A4, CYP2C8, and CYP2C9 enzymes. Co-administration with strong CYP3A Inhibitors (e.g., Ketoconazole, Ritonavir) requires dose limitation, as these substances increase Zhenale's systemic exposure. Conversely, Zhenale’s inhibition of CYP enzymes can dangerously increase the concentrations of co-administered drugs metabolized by those pathways, necessitating careful administration of such medicines at their lowest effective dose.

Other Documented Constraints

The official profile advises avoiding substances that pose an additive risk of QTc prolongation. Additionally, consumption of Grapefruit or Grapefruit Juice is restricted as it can significantly increase the drug’s blood levels. Regulatory caution is also advised for patients with Hepatic Impairment due to the potential for increased drug exposure.

Mechanism of Action

How Zhenale Works: Mechanism of Action

Modulating Receptor and Enzyme Systems

Zhenale's mechanism of action begins with its role as a modulator that acts on specific receptor and enzyme systems within cellular signaling pathways. This precise interaction either blocks receptors or inhibits key enzymes, serving to suppress the initial molecular steps of a signal transduction sequence and contributes to modulating the magnitude of pathway activation.


Reducing Signal Transduction Cascades

The initial molecular action leads to the reduction of activity within downstream signal transduction cascades. Zhenale's influence is relevant in systems where signaling mediators are prominent, supporting the alteration of signaling dynamics in defined neural or humoral pathways. This modification of molecular sequences is central to adjusting the overall flow and magnitude of communication within the affected system.


Influencing Systemic Functional Activity

By modulating these targeted pathways, Zhenale influences broader systemic functional activity. The drug engages regulatory feedback mechanisms that influence the activity level of targeted physiological responses. This results in physiological changes consistent with the drug's mechanism of action and is a consequence of the sustained modulation within the targeted biological processes.

Dosage and Administration Information

How Zhenale is Used: Official Administration Guidelines

Zhenale (Mifepristone) is administered exclusively by the oral route as a tablet, but its specific dosage and schedule are governed by the medical application, leading to two distinct administration protocols defined by established protocols.

Administration Protocols

Indication Context Dosing Schedule Frequency Pattern
Medical Termination of Pregnancy A single 200 mg oral dose One-time dose, followed by a second required medication 24 to 48 hours later.
Hypercortisolism (Cushing's Syndrome) Initial dose of 300 mg daily, titratable up to a maximum of 1200 mg per day.
Once daily for chronic management.

Key Administration Conditions

For chronic management of hypercortisolism, the medication must be taken with a meal. The tablets are required to be swallowed whole and should not be split, crushed, or chewed, a stipulation that governs the physical method of ingestion.

Population-Specific Dosing Rules

Prescribing specifications include limitations on the maximum daily dose for certain populations under the chronic regimen. For patients with either renal or hepatic impairment, the dosage should generally not exceed 600 mg per day. Furthermore, when Zhenale is used alongside strong CYP3A inhibitors, the dose is restricted to a maximum of 300 mg per day. Following the single-dose protocol, a follow-up visit with a healthcare provider is officially mandated 7 to 14 days after administration to complete the procedural sequence.

Recent Clinical Evidence

Research Evidence / Overview of Studies for Zhenale

Evidence for Use in Medical Interruption of Early Pregnancy

Research exploring the use of Zhenale (Mifepristone) in the context of medical interruption of an early intrauterine pregnancy has primarily involved a large number of Randomized Controlled Trials (RCTs). These short-term trials were used to compare the outcomes of different administration schedules of mifepristone plus a second medication (misoprostol). These studies were applied in cohorts of adult women and were specifically relevant in trials assessing short-term outcomes based on the number of weeks of gestation, typically up to 70 days. Researchers documented the rate of complete expulsion (expulsion of pregnancy without the need for surgery). These findings describe patterns observed in the studies, where rates of complete expulsion were recorded and analyzed across different gestational age groups studied.

Evidence for Use in Hypercortisolism (Cushing's Syndrome) Studies

The use of Zhenale in patients with Hypercortisolism (Cushing's Syndrome) was evaluated in specific clinical trials, including multicenter open-label studies. This research examined the medication in conditions associated with acute or disruptive episodes and systemic functional imbalance caused by high cortisol. Studies report changes measured during the study period for key metabolic markers. Researchers monitored outcomes related to systemic or functional imbalance, specifically looking at indicators of blood sugar control (like HbA1c) and changes in diastolic blood pressure. A key limitation is that sample sizes were modest due to the rarity of the condition.

Key Limitations and Areas of Research Uncertainty

For the Hypercortisolism indication, the most significant limitations are that sample sizes were modest and that long-term effects are not fully established. Due to the medication's action, standard lab tests used to measure cortisol suppression are not the primary measure of effectiveness. For both uses, the results apply only to the populations studied in the trials, and research does not determine whether an individual will respond similarly to the group patterns described in the findings.

Key Studies & References

  1. Medical management of women who request induced abortion: NICE Guideline

Frequently Asked Questions (FAQ)

Common questions about Zhenale (FAQ)

Q: How is Zhenale different from other medicines that treat similar conditions?

Official product information describes Zhenale (Mifepristone) as a Progestin Antagonist and a potent Antiglucocorticoid. This means its primary action is to block both progesterone and cortisol receptors in the body. This dual receptor blocking action is central to its specific mechanism, distinguishing it from treatments with different modes of action.

Q: Why does Zhenale have to be taken regularly?

Regulatory documents indicate that for the chronic management of Cushing’s Syndrome, the medication must be taken regularly. Taking it once daily with a meal helps to maintain consistent levels of the medicine in the blood. This consistent schedule is intended to help sustain the drug's therapeutic activity.

Q: What if I'm taking other vitamins or supplements, could that affect Zhenale?

Official guidance on this medicine advises disclosing all substances being taken to a doctor. This includes prescription and over-the-counter medicines, as well as vitamins, minerals, herbal products, and other supplements. This precaution is necessary because some supplements may influence how Zhenale is metabolized or absorbed by the body.

Q: Are the side effects of Zhenale generally mild or severe?

The official safety profile for Zhenale lists a spectrum of possible effects. The most frequently reported effects are often temporary, such as cramping or headache. However, the regulatory documents also list a rare risk of serious adverse reactions, which include conditions like significant hemorrhage (bleeding) or sepsis (serious infection).

Q: How long does it usually take to notice any effects from Zhenale?

Studies show that the drug is rapidly absorbed into the body after it is taken by mouth. Official pharmacokinetic data indicates that the highest concentrations of the medicine in the blood are usually reached about 90 minutes after administration.

Q: If I stop taking Zhenale suddenly, what happens?

For patients taking the medication long-term, official documents warn that stopping treatment abruptly may lead to adrenal insufficiency. Interruption of chronic treatment necessitates close monitoring by a healthcare professional. Should the medication need to be restarted, regulatory guidance suggests this be done at the lowest dose, under medical supervision.

Q: Is Zhenale safe to use long-term?

Long-term use is typically for the chronic management of Hypercortisolism, and this use carries specific known risks. Regulatory warnings include the risk of developing Adrenal Insufficiency, as well as changes like hypokalemia (low potassium) and issues with heart rhythm. For these reasons, long-term use is typically carried out with very close medical monitoring.

Q: Can Zhenale interact with over-the-counter pain relievers?

Official interaction documents indicate that Zhenale is a strong inhibitor of several metabolic enzymes in the body. If a common over-the-counter pain reliever is metabolized by these same enzymes, it may lead to increased concentrations of the pain reliever. The regulatory guidance advises caution and may necessitate adjustments to the dosage of the co-administered pain reliever.

Q: Can women who are pregnant or breastfeeding use Zhenale?

Pregnancy is a contraindication for the drug. For single-dose administration, official guidance indicates that breastfeeding does not need to be interrupted. For long-term management, the manufacturer's recommendation is to interrupt breastfeeding during treatment and for a period afterward due to the medicine's long presence in the body.

Q: What are the main things I should tell my doctor before starting Zhenale?

Official documents outline certain existing health conditions that should be discussed with a healthcare provider before starting this medication. This includes a history of chronic adrenal failure or any bleeding disorders. It is also necessary to discuss the use of certain medications, such as anticoagulants or corticosteroids, and report any known allergies to the drug.

Q: Does Zhenale affect my ability to drive or operate machinery?

Official reports list certain side effects that may affect physical and mental skills. These include dizziness and somnolence (sleepiness). If these effects are experienced, it may impair the ability to safely drive or operate complex machinery.

Q: What official health bodies (like the FDA or EMA) have reviewed Zhenale?

The active ingredient in this medicine has been formally reviewed by major governmental drug authorities. This includes the U.S. Food and Drug Administration (FDA). The European regulatory bodies have also authorized its use in their jurisdictions.

Q: How does the way Zhenale works compare to older treatments?

Zhenale is a chemically defined synthetic steroid whose mechanism is highly targeted. It works by blocking specific hormone receptors in the body, which differs from treatments that rely on other methods. This unique receptor blocking action is central to its therapeutic effects.

Q: Can Zhenale be used with common cold and flu medications?

Regulatory caution is advised when using Zhenale with common cold and flu medications. Zhenale is a strong inhibitor of metabolic enzymes, and some cold/flu drugs are metabolized by these enzymes. Furthermore, the label advises avoiding substances that pose an additive risk of QTc prolongation (a change in the heart's electrical activity).

Q: Does Zhenale cause weight gain or weight loss?

In clinical trials for the management of Cushing’s Syndrome, some patients reported effects related to appetite. Specifically, official documentation reports side effects that include decreased appetite and anorexia.

Q: What happens if I miss a dose of Zhenale?

Official regulatory guidance for chronic treatment indicates that if a dose is missed, taking a double dose to compensate is not recommended. The medication should be continued at its next regularly scheduled time.

Q: Is Zhenale known to cause issues with sleep?

According to the official safety documents, effects on sleep have been reported in patients taking Zhenale. These include both insomnia (trouble sleeping) and somnolence (drowsiness or excessive sleepiness).

Q: What is the purpose of the boxed warning, if Zhenale has one?

The official label for Zhenale includes a Boxed Warning to highlight important safety information for both patients and healthcare providers. This warning alerts to the rare but serious risks, specifically severe or sometimes fatal infections (sepsis) and significant hemorrhage (bleeding).

Q: Is Zhenale addictive or habit-forming?

Official regulatory documents do not classify the active ingredient, Mifepristone, as a controlled substance. Furthermore, there is no information in the regulatory labeling to indicate that this medicine is addictive or habit-forming.

Q: How long does Zhenale stay in the body after the last dose?

Pharmacokinetic data indicates that this medicine has a relatively long elimination half-life in the body. Official sources report that the average half-life is approximately 18 to 30 hours. This long duration is a factor in the drug's administration and monitoring.

Q: What is the risk of an allergic reaction to Zhenale?

Official safety information lists known hypersensitivity to the drug as a contraindication, meaning it should not be used if you have a known allergy. Allergic reactions, including anaphylaxis and angioedema, have been reported as rare, post-marketing events.

Q: Do different strengths of Zhenale have different side effect profiles?

Official safety documentation distinguishes between two main risk profiles. These profiles are based on the dose and duration of the regimen (low-dose, short-term use versus high-dose, chronic use). Therefore, the likelihood of certain side effects is directly related to the treatment plan.

Q: Is Zhenale affected by alcohol consumption?

While specific interactions with alcohol are not explicitly detailed on the label, official regulatory guidance advises caution regarding alcohol and tobacco use. This is a general precaution due to the potential for interactions with any medicine.

Q: What is the typical experience of patients taking Zhenale?

The most common reported effects reflect the experience of a typical patient starting this medicine. Official safety data frequently records headache, nausea, diarrhea, dizziness, and abdominal pain (cramping).

Q: Are there any known interactions between Zhenale and herbal teas?

Official documentation advises that all herbal products and supplements be discussed with a healthcare provider. Some herbal products can affect the drug's metabolism because they interfere with the same enzymes that process Zhenale in the body.

Q: Are there any known long-term effects after stopping Zhenale?

Due to the medicine's long half-life, certain effects may persist after the last dose, particularly following long-term use. For patients who develop adrenal insufficiency during chronic treatment, official guidance indicates that supplemental glucocorticoids may be necessary for an extended period after stopping Zhenale.

Q: Are there any mental or mood side effects linked to Zhenale?

Official safety reports indicate that some mental and mood side effects have been reported. These include anxiety, insomnia (trouble sleeping), and cases of mental depression. These effects are sometimes reported in association with problems related to the adrenal gland.

How should Zhenale be stored and disposed of?

Storage Conditions

Official labeling mandates that Zhenale (Mifepristone) tablets must be stored at controlled room temperature, specifically between 20°C to 25°C (68°F to 77°F). Brief exposure to temperatures from 15°C to 30°C is permitted, but the medicine must be protected from light and kept away from moisture.

Packaging and Child Safety

To ensure stability and integrity, the tablets must remain in the original container and be kept tightly closed. A mandatory regulatory requirement is that the product be stored out of the reach of children.

Official Disposal Rules

Unused or expired tablets should be managed according to public health guidelines. The preferred method is a drug take-back program. If this is not an option, the drug may be mixed with an undesirable substance (e.g., used coffee grounds) and placed in a sealed bag for household trash. Regulatory guidelines strictly prohibit disposal by flushing the medicine down a toilet or sink.

Attention! Always consult to a doctor or pharmacist before using pills or medicines.

Available in countries:

Equivalent of Zhenale found in:

A-Z Index: